Nasus Pharma Ltd (NSRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 06-2025 | 12-2024 | 12-2023 | |
| Assets | ||||
| Current Assets | ||||
| Cash & Cash Equivalents | 1,291 | 232 | 311 | 210 |
| Other current assets | 3,564 | 0 | 146 | 234 |
| TOTAL | $4,855 | $291 | $457 | $444 |
| Non-Current Assets | ||||
| Other Non-Current Assets | 0 | 348 | 260 | 0 |
| TOTAL | $N/A | $348 | $260 | $N/A |
| Total Assets | $5,004 | $639 | $717 | $444 |
| Liabilities | ||||
| Current Liabilities | ||||
| Short Term Debt | 0 | 2,563 | 1,802 | 2,457 |
| Accounts payable and accrued liabilities | 829 | 664 | 651 | 655 |
| Accrued Expenses | 806 | 1,179 | 987 | 616 |
| Other current liabilities | 483 | N/A | 489 | 513 |
| TOTAL | $2,163 | $4,953 | $3,929 | $4,241 |
| Non-Current Liabilities | ||||
| TOTAL | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $2,236 | $4,953 | $3,929 | $4,241 |
| Shareholders' Equity | ||||
| Common Shares | 0 | 20 | 20 | 19 |
| Retained earnings | -18,520 | -13,916 | -12,664 | -11,132 |
| TOTAL | $2,768 | $-4,314 | $-3,212 | $-3,797 |
| Total Liabilities And Equity | $5,004 | $639 | $717 | $444 |